Axol Bioscience Acquires Newcells Biotech's Ophthalmology Business

Axol Bioscience Acquires Phenocell

October 21, 2024

Biotechnology

Axol Bioscience Ltd. has fully acquired Phenocell SAS, adding Phenocell’s iPSC-derived skin and retinal cell lines and custom bioassay services to Axol’s drug discovery product portfolio. The acquisition expands Axol’s capabilities into ophthalmology and dermatology (including AMD and cosmetics testing); financial terms were not disclosed.

Merck to Acquire EyeBio for up to $3 Billion

May 29, 2024

Biotechnology

Merck (through a subsidiary) will acquire Eyebiotech Limited (EyeBio) for up to $3.0 billion — $1.3 billion upfront in cash plus up to $1.7 billion in development, regulatory and commercial milestones. The acquisition—expected to close in Q3 2024 and to be accounted for as an asset acquisition—adds EyeBio's ophthalmology-focused pipeline, including lead candidate Restoret (EYE103), to Merck's growing ophthalmology presence.

AnaBios Acquires Cell Systems

April 4, 2023

Biotechnology

AnaBios Corporation has acquired Cell Systems, a Kirkland, Washington supplier of human primary cells and cell culture media, to expand its human tissue and cell portfolio and accelerate translational drug discovery. Financing for the transaction was provided by AnaBios' existing investors, including Ampersand Capital Partners; financial terms were not disclosed.

Leica Biosystems Acquires Cell IDx

November 8, 2022

Biotechnology

Leica Biosystems has acquired Cell IDx, a San Diego-based leader in multiplexed tissue profiling, integrating Cell IDx's UltraPlex multiplex IHC technology with Leica's BOND RX automation to expand translational research and multiplexing capabilities. The deal advances Leica's research-focused staining and imaging portfolio and brings scale-up and medical/scientific affairs support for Cell IDx customers.

Axion BioSystems Acquires CytoSMART Technologies

March 21, 2022

Medical Devices

Axion BioSystems has acquired Netherlands-based CytoSMART Technologies, a developer of kinetic live-cell imaging systems and AI-powered image analysis tools. The acquisition expands Axion's product portfolio and capabilities in live-cell imaging to support research in stem cell biology, immuno-oncology, cell-based therapies, and drug discovery.

Quanterix Corporation Acquires Akoya Biosciences

July 8, 2025

Medical Devices

Quanterix Corporation has completed its acquisition of Akoya Biosciences, combining Quanterix's ultra‑sensitive blood biomarker detection platform with Akoya's spatial biology imaging and reagents. Under the amended merger agreement, Quanterix issued approximately 7.8 million shares and paid about $20 million in cash to Akoya equity holders; the combined business is expected to expand the company's served addressable market and accelerate the path to profitability.